Carlos Durán
- ORCID iD
-
0000-0003-1853-3641
Show
Sort by
-
- Journal Article
- A1
- open access
Potential negative impact of reputed regulators' decisions on the approval status of new cancer drugs in Latin American countries : a descriptive analysis
-
- Journal Article
- A1
- open access
Preprints in times of COVID19 : the time is ripe for agreeing on terminology and good practices
-
- PhD Thesis
- open access
Regulation, consumption and expenditures of new cancer drugs in Ecuador and Latin America
(2021) -
- Journal Article
- A1
- open access
Essential medicines in universal health coverage : a scoping review of public health law interventions and how they are measured in five middle-income countries
-
- Journal Article
- A1
- open access
EMA and FDA decisions based on flawed evidence to approve new cancer drugs negatively affect Latin American patients
-
Policies influencing access to new targeted oncologic drugs in Ecuadorian hospitals : an interrupted time series analysis
-
Sharp rise in the expenditures of targeted drugs in Ecuador : five-year (2010-2014) consumption of oncologic drugs in public and private hospitals
-
Pharmaceutical policy in Ecuador
-
Anticholinergic exposure in a cohort of adults aged 80 years and over : associations of the MARANTE scale with mortality and hospitalisation
-
A novel scale linking potency and dosage to estimate anticholinergic exposure in older adults : the Muscarinic Acetylcholinergic Receptor ANTagonist Exposure Scale